Partnerships Are Key To Foundation Medicine's Success
Executive Summary
Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.
You may also be interested in...
UX Upgrade For Genomics Reports, AI Diagnostic Partnership Announced
Foundation Medicine, NVIDIA and Nuance were among the companies that announced key initiatives during the HLTH conference in Las Vegas this week.
FDA Approves Foundation Medicine Liquid Biopsy Test As Companion Diagnostic For Lynparza
The US FDA expanded the use of FoundationOne Liquid CDx as a companion diagnostic for certain prostate cancer patients eligible for treatment with olaparib.
Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test
Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.